ID   KGP1_HUMAN              Reviewed;         671 AA.
AC   Q13976; A5YM56; B3KSF3; E2PU10; P14619; Q5JP05; Q5JSJ6; Q6P5T7;
DT   30-MAY-2000, integrated into UniProtKB/Swiss-Prot.
DT   23-JAN-2007, sequence version 3.
DT   12-APR-2017, entry version 174.
DE   RecName: Full=cGMP-dependent protein kinase 1;
DE            Short=cGK 1;
DE            Short=cGK1;
DE            EC=2.7.11.12;
DE   AltName: Full=cGMP-dependent protein kinase I;
DE            Short=cGKI;
GN   Name=PRKG1; Synonyms=PRKG1B, PRKGR1A, PRKGR1B;
OS   Homo sapiens (Human).
OC   Eukaryota; Metazoa; Chordata; Craniata; Vertebrata; Euteleostomi;
OC   Mammalia; Eutheria; Euarchontoglires; Primates; Haplorrhini;
OC   Catarrhini; Hominidae; Homo.
OX   NCBI_TaxID=9606;
RN   [1]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM BETA).
RC   TISSUE=Placenta;
RX   PubMed=2792381; DOI=10.1016/0014-5793(89)81114-7;
RA   Sandberg M., Natarajan V., Ronander I., Kalderon D., Walter U.,
RA   Lohmann S.M., Jahnsen T.;
RT   "Molecular cloning and predicted full-length amino acid sequence of
RT   the type I beta isozyme of cGMP-dependent protein kinase from human
RT   placenta. Tissue distribution and developmental changes in rat.";
RL   FEBS Lett. 255:321-329(1989).
RN   [2]
RP   SEQUENCE REVISION.
RA   Sandberg M.;
RL   Submitted (OCT-1989) to the EMBL/GenBank/DDBJ databases.
RN   [3]
RP   NUCLEOTIDE SEQUENCE [MRNA] (ISOFORM ALPHA).
RC   TISSUE=Lung;
RX   PubMed=8613202; DOI=10.1161/01.HYP.27.3.552;
RA   Tamura N., Itoh H., Ogawa Y., Nakagawa O., Harada M., Chun T.,
RA   Suga S., Yoshimasa T., Nakao K.;
RT   "cDNA cloning and gene expression of human type Ialpha cGMP-dependent
RT   protein kinase.";
RL   Hypertension 27:552-557(1996).
RN   [4]
RP   NUCLEOTIDE SEQUENCE [GENOMIC DNA], AND TISSUE SPECIFICITY.
RX   PubMed=9192852; DOI=10.1006/geno.1997.4743;
RA   Orstavik S., Natarajan V., Tasken K., Jahnsen T., Sandberg M.;
RT   "Characterization of the human gene encoding the type I alpha and type
RT   I beta cGMP-dependent protein kinase (PRKG1).";
RL   Genomics 42:311-318(1997).
RN   [5]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM 3).
RC   TISSUE=Testis;
RX   PubMed=14702039; DOI=10.1038/ng1285;
RA   Ota T., Suzuki Y., Nishikawa T., Otsuki T., Sugiyama T., Irie R.,
RA   Wakamatsu A., Hayashi K., Sato H., Nagai K., Kimura K., Makita H.,
RA   Sekine M., Obayashi M., Nishi T., Shibahara T., Tanaka T., Ishii S.,
RA   Yamamoto J., Saito K., Kawai Y., Isono Y., Nakamura Y., Nagahari K.,
RA   Murakami K., Yasuda T., Iwayanagi T., Wagatsuma M., Shiratori A.,
RA   Sudo H., Hosoiri T., Kaku Y., Kodaira H., Kondo H., Sugawara M.,
RA   Takahashi M., Kanda K., Yokoi T., Furuya T., Kikkawa E., Omura Y.,
RA   Abe K., Kamihara K., Katsuta N., Sato K., Tanikawa M., Yamazaki M.,
RA   Ninomiya K., Ishibashi T., Yamashita H., Murakawa K., Fujimori K.,
RA   Tanai H., Kimata M., Watanabe M., Hiraoka S., Chiba Y., Ishida S.,
RA   Ono Y., Takiguchi S., Watanabe S., Yosida M., Hotuta T., Kusano J.,
RA   Kanehori K., Takahashi-Fujii A., Hara H., Tanase T.-O., Nomura Y.,
RA   Togiya S., Komai F., Hara R., Takeuchi K., Arita M., Imose N.,
RA   Musashino K., Yuuki H., Oshima A., Sasaki N., Aotsuka S.,
RA   Yoshikawa Y., Matsunawa H., Ichihara T., Shiohata N., Sano S.,
RA   Moriya S., Momiyama H., Satoh N., Takami S., Terashima Y., Suzuki O.,
RA   Nakagawa S., Senoh A., Mizoguchi H., Goto Y., Shimizu F., Wakebe H.,
RA   Hishigaki H., Watanabe T., Sugiyama A., Takemoto M., Kawakami B.,
RA   Yamazaki M., Watanabe K., Kumagai A., Itakura S., Fukuzumi Y.,
RA   Fujimori Y., Komiyama M., Tashiro H., Tanigami A., Fujiwara T.,
RA   Ono T., Yamada K., Fujii Y., Ozaki K., Hirao M., Ohmori Y.,
RA   Kawabata A., Hikiji T., Kobatake N., Inagaki H., Ikema Y., Okamoto S.,
RA   Okitani R., Kawakami T., Noguchi S., Itoh T., Shigeta K., Senba T.,
RA   Matsumura K., Nakajima Y., Mizuno T., Morinaga M., Sasaki M.,
RA   Togashi T., Oyama M., Hata H., Watanabe M., Komatsu T.,
RA   Mizushima-Sugano J., Satoh T., Shirai Y., Takahashi Y., Nakagawa K.,
RA   Okumura K., Nagase T., Nomura N., Kikuchi H., Masuho Y., Yamashita R.,
RA   Nakai K., Yada T., Nakamura Y., Ohara O., Isogai T., Sugano S.;
RT   "Complete sequencing and characterization of 21,243 full-length human
RT   cDNAs.";
RL   Nat. Genet. 36:40-45(2004).
RN   [6]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BETA).
RC   TISSUE=Cervix;
RX   PubMed=17974005; DOI=10.1186/1471-2164-8-399;
RA   Bechtel S., Rosenfelder H., Duda A., Schmidt C.P., Ernst U.,
RA   Wellenreuther R., Mehrle A., Schuster C., Bahr A., Bloecker H.,
RA   Heubner D., Hoerlein A., Michel G., Wedler H., Koehrer K.,
RA   Ottenwaelder B., Poustka A., Wiemann S., Schupp I.;
RT   "The full-ORF clone resource of the German cDNA consortium.";
RL   BMC Genomics 8:399-399(2007).
RN   [7]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RX   PubMed=15164054; DOI=10.1038/nature02462;
RA   Deloukas P., Earthrowl M.E., Grafham D.V., Rubenfield M., French L.,
RA   Steward C.A., Sims S.K., Jones M.C., Searle S., Scott C., Howe K.,
RA   Hunt S.E., Andrews T.D., Gilbert J.G.R., Swarbreck D., Ashurst J.L.,
RA   Taylor A., Battles J., Bird C.P., Ainscough R., Almeida J.P.,
RA   Ashwell R.I.S., Ambrose K.D., Babbage A.K., Bagguley C.L., Bailey J.,
RA   Banerjee R., Bates K., Beasley H., Bray-Allen S., Brown A.J.,
RA   Brown J.Y., Burford D.C., Burrill W., Burton J., Cahill P., Camire D.,
RA   Carter N.P., Chapman J.C., Clark S.Y., Clarke G., Clee C.M., Clegg S.,
RA   Corby N., Coulson A., Dhami P., Dutta I., Dunn M., Faulkner L.,
RA   Frankish A., Frankland J.A., Garner P., Garnett J., Gribble S.,
RA   Griffiths C., Grocock R., Gustafson E., Hammond S., Harley J.L.,
RA   Hart E., Heath P.D., Ho T.P., Hopkins B., Horne J., Howden P.J.,
RA   Huckle E., Hynds C., Johnson C., Johnson D., Kana A., Kay M.,
RA   Kimberley A.M., Kershaw J.K., Kokkinaki M., Laird G.K., Lawlor S.,
RA   Lee H.M., Leongamornlert D.A., Laird G., Lloyd C., Lloyd D.M.,
RA   Loveland J., Lovell J., McLaren S., McLay K.E., McMurray A.,
RA   Mashreghi-Mohammadi M., Matthews L., Milne S., Nickerson T.,
RA   Nguyen M., Overton-Larty E., Palmer S.A., Pearce A.V., Peck A.I.,
RA   Pelan S., Phillimore B., Porter K., Rice C.M., Rogosin A., Ross M.T.,
RA   Sarafidou T., Sehra H.K., Shownkeen R., Skuce C.D., Smith M.,
RA   Standring L., Sycamore N., Tester J., Thorpe A., Torcasso W.,
RA   Tracey A., Tromans A., Tsolas J., Wall M., Walsh J., Wang H.,
RA   Weinstock K., West A.P., Willey D.L., Whitehead S.L., Wilming L.,
RA   Wray P.W., Young L., Chen Y., Lovering R.C., Moschonas N.K.,
RA   Siebert R., Fechtel K., Bentley D., Durbin R.M., Hubbard T.,
RA   Doucette-Stamm L., Beck S., Smith D.R., Rogers J.;
RT   "The DNA sequence and comparative analysis of human chromosome 10.";
RL   Nature 429:375-381(2004).
RN   [8]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE GENOMIC DNA].
RA   Mural R.J., Istrail S., Sutton G.G., Florea L., Halpern A.L.,
RA   Mobarry C.M., Lippert R., Walenz B., Shatkay H., Dew I., Miller J.R.,
RA   Flanigan M.J., Edwards N.J., Bolanos R., Fasulo D., Halldorsson B.V.,
RA   Hannenhalli S., Turner R., Yooseph S., Lu F., Nusskern D.R.,
RA   Shue B.C., Zheng X.H., Zhong F., Delcher A.L., Huson D.H.,
RA   Kravitz S.A., Mouchard L., Reinert K., Remington K.A., Clark A.G.,
RA   Waterman M.S., Eichler E.E., Adams M.D., Hunkapiller M.W., Myers E.W.,
RA   Venter J.C.;
RL   Submitted (JUL-2005) to the EMBL/GenBank/DDBJ databases.
RN   [9]
RP   NUCLEOTIDE SEQUENCE [LARGE SCALE MRNA] (ISOFORM BETA).
RX   PubMed=15489334; DOI=10.1101/gr.2596504;
RG   The MGC Project Team;
RT   "The status, quality, and expansion of the NIH full-length cDNA
RT   project: the Mammalian Gene Collection (MGC).";
RL   Genome Res. 14:2121-2127(2004).
RN   [10]
RP   FUNCTION IN PHOSPHORYLATION OF VASP.
RX   PubMed=8182057;
RA   Butt E., Abel K., Krieger M., Palm D., Hoppe V., Hoppe J., Walter U.;
RT   "cAMP- and cGMP-dependent protein kinase phosphorylation sites of the
RT   focal adhesion vasodilator-stimulated phosphoprotein (VASP) in vitro
RT   and in intact human platelets.";
RL   J. Biol. Chem. 269:14509-14517(1994).
RN   [11]
RP   INTERACTION WITH PPP1R12A, SUBUNIT, MUTAGENESIS OF LEU-12; ILE-19;
RP   LEU-26; ILE-33 AND LEU-40, AND FUNCTION.
RX   PubMed=10567269; DOI=10.1126/science.286.5444.1583;
RA   Surks H.K., Mochizuki N., Kasai Y., Georgescu S.P., Tang K.M., Ito M.,
RA   Lincoln T.M., Mendelsohn M.E.;
RT   "Regulation of myosin phosphatase by a specific interaction with cGMP-
RT   dependent protein kinase Ialpha.";
RL   Science 286:1583-1587(1999).
RN   [12]
RP   FUNCTION IN PHOSPHORYLATION OF RHOA.
RX   PubMed=11162591; DOI=10.1006/bbrc.2000.4194;
RA   Sawada N., Itoh H., Yamashita J., Doi K., Inoue M., Masatsugu K.,
RA   Fukunaga Y., Sakaguchi S., Sone M., Yamahara K., Yurugi T., Nakao K.;
RT   "cGMP-dependent protein kinase phosphorylates and inactivates RhoA.";
RL   Biochem. Biophys. Res. Commun. 280:798-805(2001).
RN   [13]
RP   FUNCTION IN PHOSPHORYLATION OF GTF2I, AND INTERACTION WITH GTF2I.
RX   PubMed=12082086; DOI=10.1074/jbc.M112332200;
RA   Casteel D.E., Zhuang S., Gudi T., Tang J., Vuica M., Desiderio S.,
RA   Pilz R.B.;
RT   "cGMP-dependent protein kinase I beta physically and functionally
RT   interacts with the transcriptional regulator TFII-I.";
RL   J. Biol. Chem. 277:32003-32014(2002).
RN   [14]
RP   FUNCTION IN PHOSPHORYLATION OF PDE5.
RX   PubMed=11723116; DOI=10.1074/jbc.M106562200;
RA   Rybalkin S.D., Rybalkina I.G., Feil R., Hofmann F., Beavo J.A.;
RT   "Regulation of cGMP-specific phosphodiesterase (PDE5) phosphorylation
RT   in smooth muscle cells.";
RL   J. Biol. Chem. 277:3310-3317(2002).
RN   [15]
RP   FUNCTION IN PHOSPHORYLATION OF RGS2, AND INTERACTION WITH RGS2.
RX   PubMed=14608379; DOI=10.1038/nm958;
RA   Tang K.M., Wang G.R., Lu P., Karas R.H., Aronovitz M., Heximer S.P.,
RA   Kaltenbronn K.M., Blumer K.J., Siderovski D.P., Zhu Y.,
RA   Mendelsohn M.E.;
RT   "Regulator of G-protein signaling-2 mediates vascular smooth muscle
RT   relaxation and blood pressure.";
RL   Nat. Med. 9:1506-1512(2003).
RN   [16]
RP   FUNCTION.
RX   PubMed=15194681; DOI=10.1074/jbc.M405957200;
RA   Wooldridge A.A., MacDonald J.A., Erdodi F., Ma C., Borman M.A.,
RA   Hartshorne D.J., Haystead T.A.J.;
RT   "Smooth muscle phosphatase is regulated in vivo by exclusion of
RT   phosphorylation of threonine 696 of MYPT1 by phosphorylation of Serine
RT   695 in response to cyclic nucleotides.";
RL   J. Biol. Chem. 279:34496-34504(2004).
RN   [17]
RP   FUNCTION IN THE INHIBITION OF PLATELET AGGREGATION, FUNCTION IN
RP   PHOSPHORYLATION OF MRVI1, SUBCELLULAR LOCATION, AND INTERACTION WITH
RP   MRVI1 AND ITPR1.
RX   PubMed=16990611; DOI=10.1182/blood-2005-10-026294;
RA   Antl M., von Bruehl M.-L., Eiglsperger C., Werner M., Konrad I.,
RA   Kocher T., Wilm M., Hofmann F., Massberg S., Schlossmann J.;
RT   "IRAG mediates NO/cGMP-dependent inhibition of platelet aggregation
RT   and thrombus formation.";
RL   Blood 109:552-559(2007).
RN   [18]
RP   INTERACTION WITH PPP1R12A.
RX   PubMed=17904578; DOI=10.1016/j.jmb.2007.08.049;
RA   Lee E., Hayes D.B., Langsetmo K., Sundberg E.J., Tao T.C.;
RT   "Interactions between the leucine-zipper motif of cGMP-dependent
RT   protein kinase and the C-terminal region of the targeting subunit of
RT   myosin light chain phosphatase.";
RL   J. Mol. Biol. 373:1198-1212(2007).
RN   [19]
RP   INTERACTION WITH PPP1R12A, AND SUBUNIT.
RX   PubMed=18782776; DOI=10.1074/jbc.M804916200;
RA   Sharma A.K., Zhou G.-P., Kupferman J., Surks H.K., Christensen E.N.,
RA   Chou J.J., Mendelsohn M.E., Rigby A.C.;
RT   "Probing the interaction between the coiled coil leucine zipper of
RT   cGMP-dependent protein kinase Ialpha and the C terminus of the myosin
RT   binding subunit of the myosin light chain phosphatase.";
RL   J. Biol. Chem. 283:32860-32869(2008).
RN   [20]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=19369195; DOI=10.1074/mcp.M800588-MCP200;
RA   Oppermann F.S., Gnad F., Olsen J.V., Hornberger R., Greff Z., Keri G.,
RA   Mann M., Daub H.;
RT   "Large-scale proteomics analysis of the human kinome.";
RL   Mol. Cell. Proteomics 8:1751-1764(2009).
RN   [21]
RP   REVIEW.
RX   PubMed=20716671; DOI=10.1124/pr.110.002907;
RA   Francis S.H., Busch J.L., Corbin J.D., Sibley D.;
RT   "cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric
RT   oxide and cGMP action.";
RL   Pharmacol. Rev. 62:525-563(2010).
RN   [22]
RP   IDENTIFICATION BY MASS SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=21269460; DOI=10.1186/1752-0509-5-17;
RA   Burkard T.R., Planyavsky M., Kaupe I., Breitwieser F.P.,
RA   Buerckstuemmer T., Bennett K.L., Superti-Furga G., Colinge J.;
RT   "Initial characterization of the human central proteome.";
RL   BMC Syst. Biol. 5:17-17(2011).
RN   [23]
RP   FUNCTION (ISOFORM ALPHA) IN PHOSPHORYLATION OF TRPC7, INTERACTION WITH
RP   TRPC7, AND SUBCELLULAR LOCATION.
RX   PubMed=21402151; DOI=10.1016/j.cellsig.2011.03.005;
RA   Yuasa K., Matsuda T., Tsuji A.;
RT   "Functional regulation of transient receptor potential canonical 7 by
RT   cGMP-dependent protein kinase Ialpha.";
RL   Cell. Signal. 23:1179-1187(2011).
RN   [24]
RP   ACETYLATION [LARGE SCALE ANALYSIS] AT SER-2, CLEAVAGE OF INITIATOR
RP   METHIONINE [LARGE SCALE ANALYSIS], AND IDENTIFICATION BY MASS
RP   SPECTROMETRY [LARGE SCALE ANALYSIS].
RX   PubMed=22223895; DOI=10.1074/mcp.M111.015131;
RA   Bienvenut W.V., Sumpton D., Martinez A., Lilla S., Espagne C.,
RA   Meinnel T., Giglione C.;
RT   "Comparative large-scale characterisation of plant vs. mammal proteins
RT   reveals similar and idiosyncratic N-alpha acetylation features.";
RL   Mol. Cell. Proteomics 11:M111.015131-M111.015131(2012).
RN   [25]
RP   STRUCTURE BY NMR OF 2-58, INTERACTION WITH PPP1R12A, SUBUNIT, AND
RP   COILED-COIL.
RX   PubMed=16131665; DOI=10.1110/ps.051528905;
RA   Schnell J.R., Zhou G.-P., Zweckstetter M., Rigby A.C., Chou J.J.;
RT   "Rapid and accurate structure determination of coiled-coil domains
RT   using NMR dipolar couplings: application to cGMP-dependent protein
RT   kinase Ialpha.";
RL   Protein Sci. 14:2421-2428(2005).
RN   [26]
RP   X-RAY CRYSTALLOGRAPHY (2.27 ANGSTROMS) OF 4-55 (ISOFORM BETA), AND
RP   SUBUNIT.
RX   PubMed=20826808; DOI=10.1074/jbc.C110.161430;
RA   Casteel D.E., Smith-Nguyen E.V., Sankaran B., Roh S.H., Pilz R.B.,
RA   Kim C.;
RT   "A crystal structure of the cyclic GMP-dependent protein kinase
RT   I{beta} dimerization/docking domain reveals molecular details of
RT   isoform-specific anchoring.";
RL   J. Biol. Chem. 285:32684-32688(2010).
RN   [27]
RP   X-RAY CRYSTALLOGRAPHY (2.49 ANGSTROMS) OF 92-227 (ISOFORM BETA) IN
RP   COMPLEX WITH CGMP AND CAMP.
RX   PubMed=21526164; DOI=10.1371/journal.pone.0018413;
RA   Kim J.J., Casteel D.E., Huang G., Kwon T.H., Ren R.K., Zwart P.,
RA   Headd J.J., Brown N.G., Chow D.C., Palzkill T., Kim C.;
RT   "Co-crystal structures of PKG Ibeta (92-227) with cGMP and cAMP reveal
RT   the molecular details of cyclic-nucleotide binding.";
RL   PLoS ONE 6:E18413-E18413(2011).
RN   [28]
RP   X-RAY CRYSTALLOGRAPHY (1.32 ANGSTROMS) OF 204-354 (ISOFORM BETA) IN
RP   COMPLEX WITH CAMP AND CGMP.
RX   PubMed=25271401; DOI=10.1021/bi501012v;
RA   Huang G.Y., Gerlits O.O., Blakeley M.P., Sankaran B., Kovalevsky A.Y.,
RA   Kim C.;
RT   "Neutron diffraction reveals hydrogen bonds critical for cGMP-
RT   selective activation: insights for cGMP-dependent protein kinase
RT   agonist design.";
RL   Biochemistry 53:6725-6727(2014).
RN   [29]
RP   X-RAY CRYSTALLOGRAPHY (1.65 ANGSTROMS) OF 204-354 (ISOFORM BETA) IN
RP   COMPLEX WITH CGMP, AND MUTAGENESIS OF LEU-281; ARG-282; THR-302 AND
RP   TYR-336.
RX   PubMed=24239458; DOI=10.1016/j.str.2013.09.021;
RA   Huang G.Y., Kim J.J., Reger A.S., Lorenz R., Moon E.W., Zhao C.,
RA   Casteel D.E., Bertinetti D., Vanschouwen B., Selvaratnam R.,
RA   Pflugrath J.W., Sankaran B., Melacini G., Herberg F.W., Kim C.;
RT   "Structural basis for cyclic-nucleotide selectivity and cGMP-selective
RT   activation of PKG I.";
RL   Structure 22:116-124(2014).
RN   [30]
RP   VARIANTS [LARGE SCALE ANALYSIS] VAL-249 AND SER-267.
RX   PubMed=17344846; DOI=10.1038/nature05610;
RA   Greenman C., Stephens P., Smith R., Dalgliesh G.L., Hunter C.,
RA   Bignell G., Davies H., Teague J., Butler A., Stevens C., Edkins S.,
RA   O'Meara S., Vastrik I., Schmidt E.E., Avis T., Barthorpe S.,
RA   Bhamra G., Buck G., Choudhury B., Clements J., Cole J., Dicks E.,
RA   Forbes S., Gray K., Halliday K., Harrison R., Hills K., Hinton J.,
RA   Jenkinson A., Jones D., Menzies A., Mironenko T., Perry J., Raine K.,
RA   Richardson D., Shepherd R., Small A., Tofts C., Varian J., Webb T.,
RA   West S., Widaa S., Yates A., Cahill D.P., Louis D.N., Goldstraw P.,
RA   Nicholson A.G., Brasseur F., Looijenga L., Weber B.L., Chiew Y.-E.,
RA   DeFazio A., Greaves M.F., Green A.R., Campbell P., Birney E.,
RA   Easton D.F., Chenevix-Trench G., Tan M.-H., Khoo S.K., Teh B.T.,
RA   Yuen S.T., Leung S.Y., Wooster R., Futreal P.A., Stratton M.R.;
RT   "Patterns of somatic mutation in human cancer genomes.";
RL   Nature 446:153-158(2007).
RN   [31]
RP   VARIANT AAT8 GLN-177, VARIANTS PHE-474 AND ALA-666, AND
RP   CHARACTERIZATION OF VARIANT AAT8 GLN-177.
RX   PubMed=23910461; DOI=10.1016/j.ajhg.2013.06.019;
RG   GenTAC Registry Consortium;
RG   National Heart, Lung, and Blood Institute Grand Opportunity Exome Sequencing Project;
RA   Guo D.C., Regalado E., Casteel D.E., Santos-Cortez R.L., Gong L.,
RA   Kim J.J., Dyack S., Horne S.G., Chang G., Jondeau G., Boileau C.,
RA   Coselli J.S., Li Z., Leal S.M., Shendure J., Rieder M.J.,
RA   Bamshad M.J., Nickerson D.A., Kim C., Milewicz D.M.;
RT   "Recurrent gain-of-function mutation in PRKG1 causes thoracic aortic
RT   aneurysms and acute aortic dissections.";
RL   Am. J. Hum. Genet. 93:398-404(2013).
CC   -!- FUNCTION: Serine/threonine protein kinase that acts as key
CC       mediator of the nitric oxide (NO)/cGMP signaling pathway. GMP
CC       binding activates PRKG1, which phosphorylates serines and
CC       threonines on many cellular proteins. Numerous protein targets for
CC       PRKG1 phosphorylation are implicated in modulating cellular
CC       calcium, but the contribution of each of these targets may vary
CC       substantially among cell types. Proteins that are phosphorylated
CC       by PRKG1 regulate platelet activation and adhesion, smooth muscle
CC       contraction, cardiac function, gene expression, feedback of the
CC       NO-signaling pathway, and other processes involved in several
CC       aspects of the CNS like axon guidance, hippocampal and cerebellar
CC       learning, circadian rhythm and nociception. Smooth muscle
CC       relaxation is mediated through lowering of intracellular free
CC       calcium, by desensitization of contractile proteins to calcium,
CC       and by decrease in the contractile state of smooth muscle or in
CC       platelet activation. Regulates intracellular calcium levels via
CC       several pathways: phosphorylates MRVI1/IRAG and inhibits IP3-
CC       induced Ca(2+) release from intracellular stores, phosphorylation
CC       of KCNMA1 (BKCa) channels decreases intracellular Ca(2+) levels,
CC       which leads to increased opening of this channel. PRKG1
CC       phosphorylates the canonical transient receptor potential channel
CC       (TRPC) family which inactivates the associated inward calcium
CC       current. Another mode of action of NO/cGMP/PKGI signaling involves
CC       PKGI-mediated inactivation of the Ras homolog gene family member A
CC       (RhoA). Phosphorylation of RHOA by PRKG1 blocks the action of this
CC       protein in myriad processes: regulation of RHOA translocation;
CC       decreasing contraction; controlling vesicle trafficking, reduction
CC       of myosin light chain phosphorylation resulting in vasorelaxation.
CC       Activation of PRKG1 by NO signaling alters also gene expression in
CC       a number of tissues. In smooth muscle cells, increased cGMP and
CC       PRKG1 activity influence expression of smooth muscle-specific
CC       contractile proteins, levels of proteins in the NO/cGMP signaling
CC       pathway, down-regulation of the matrix proteins osteopontin and
CC       thrombospondin-1 to limit smooth muscle cell migration and
CC       phenotype. Regulates vasodilator-stimulated phosphoprotein (VASP)
CC       functions in platelets and smooth muscle.
CC       {ECO:0000269|PubMed:10567269, ECO:0000269|PubMed:11162591,
CC       ECO:0000269|PubMed:11723116, ECO:0000269|PubMed:12082086,
CC       ECO:0000269|PubMed:14608379, ECO:0000269|PubMed:15194681,
CC       ECO:0000269|PubMed:16990611, ECO:0000269|PubMed:8182057}.
CC   -!- CATALYTIC ACTIVITY: ATP + a protein = ADP + a phosphoprotein.
CC   -!- ENZYME REGULATION: In the absence of cGMP, PRKG1 activity is
CC       suppressed by autoinhibitory contacts.
CC   -!- SUBUNIT: Isoform alpha: parallel homodimer or heterodimer and also
CC       heterotetramer. Interacts directly with PPP1R12A. Non-covalent
CC       dimer of dimer of PRKG1-PRKG1 and PPP1R12A-PPP1R12A. This
CC       interaction targets PRKG1 to stress fibers to mediate smooth
CC       muscle cell relaxation and vasodilation in responses to rises in
CC       cGMP. Isoform beta: antiparallel homodimer. Part of cGMP kinase
CC       signaling complex at least composed of ACTA2/alpha-actin,
CC       CNN1/calponin H1, PLN/phospholamban, PRKG1 and ITPR1 (By
CC       similarity). Interacts with MRVI1. Forms a stable complex with
CC       ITPR1, MRVI1, and isoform beta of PRKG1. Interacts with TRPC7 (via
CC       ankyrin repeat domain). Isoform alpha interacts with RGS2.
CC       Interacts with GTF2I. {ECO:0000250, ECO:0000269|PubMed:10567269,
CC       ECO:0000269|PubMed:12082086, ECO:0000269|PubMed:14608379,
CC       ECO:0000269|PubMed:16131665, ECO:0000269|PubMed:16990611,
CC       ECO:0000269|PubMed:17904578, ECO:0000269|PubMed:18782776,
CC       ECO:0000269|PubMed:20826808, ECO:0000269|PubMed:21402151}.
CC   -!- INTERACTION:
CC       Q13873:BMPR2; NbExp=2; IntAct=EBI-3952014, EBI-527196;
CC       Q86V42:FAM124A; NbExp=3; IntAct=EBI-3952014, EBI-744506;
CC       P25791:LMO2; NbExp=3; IntAct=EBI-3952014, EBI-739696;
CC       O15015:ZNF646; NbExp=3; IntAct=EBI-3952014, EBI-745608;
CC   -!- SUBCELLULAR LOCATION: Cytoplasm {ECO:0000250}. Note=Colocalized
CC       with TRPC7 in the plasma membrane. {ECO:0000250}.
CC   -!- ALTERNATIVE PRODUCTS:
CC       Event=Alternative splicing; Named isoforms=3;
CC       Name=Alpha; Synonyms=CGK1-alpha;
CC         IsoId=Q13976-1; Sequence=Displayed;
CC       Name=Beta; Synonyms=CGK1-beta;
CC         IsoId=Q13976-2, P14619-1;
CC         Sequence=VSP_038714;
CC       Name=3;
CC         IsoId=Q13976-3; Sequence=VSP_055541, VSP_055542;
CC         Note=No experimental confirmation available.;
CC   -!- TISSUE SPECIFICITY: Primarily expressed in lung and placenta.
CC       {ECO:0000269|PubMed:9192852}.
CC   -!- DOMAIN: Composed of an N-terminal leucine-zipper domain followed
CC       by an autoinhibitory domain, which mediate homodimer formation and
CC       inhibit kinase activity, respectively. Next, two cGMP-binding
CC       domains are followed by the catalytic domain at the C-terminus.
CC       Binding of cGMP to cGMP-binding domains results in a
CC       conformational change that activates kinase activity by removing
CC       the autoinhibitory domain from the catalytic cleft leaving the
CC       catalytic domain free to phosphorylate downstream substrates.
CC       Isoforms alpha and beta have identical cGMP-binding and catalytic
CC       domains but differ in their leucine zipper and autoinhibitory
CC       sequences and therefore differ in their dimerization substrates
CC       and kinase enzyme activity.
CC   -!- DOMAIN: Heterotetramerization is mediated by the interaction
CC       between a coiled-coil of PRKG1 and the leucine/isoleucine zipper
CC       of PPP1R12A/MBS, the myosin-binding subunit of the myosin
CC       phosphatase.
CC   -!- PTM: Autophosphorylation increases kinase activity.
CC   -!- PTM: 65 kDa monomer is produced by proteolytic cleavage.
CC       {ECO:0000250}.
CC   -!- DISEASE: Aortic aneurysm, familial thoracic 8 (AAT8) [MIM:615436]:
CC       A disease characterized by permanent dilation of the thoracic
CC       aorta usually due to degenerative changes in the aortic wall. It
CC       is primarily associated with a characteristic histologic
CC       appearance known as 'medial necrosis' or 'Erdheim cystic medial
CC       necrosis' in which there is degeneration and fragmentation of
CC       elastic fibers, loss of smooth muscle cells, and an accumulation
CC       of basophilic ground substance. {ECO:0000269|PubMed:23910461}.
CC       Note=The disease is caused by mutations affecting the gene
CC       represented in this entry.
CC   -!- SIMILARITY: Belongs to the protein kinase superfamily. AGC Ser/Thr
CC       protein kinase family. cGMP subfamily. {ECO:0000305}.
CC   -----------------------------------------------------------------------
CC   Copyrighted by the UniProt Consortium, see http://www.uniprot.org/terms
CC   Distributed under the Creative Commons Attribution-NoDerivs License
CC   -----------------------------------------------------------------------
DR   EMBL; Y07512; CAA68810.1; -; mRNA.
DR   EMBL; D45864; BAA08297.1; -; mRNA.
DR   EMBL; AK093436; BAG52715.1; -; mRNA.
DR   EMBL; EF560730; ABQ59040.1; -; mRNA.
DR   EMBL; Z92867; CAB07436.1; -; Genomic_DNA.
DR   EMBL; Z92869; CAB07436.1; JOINED; Genomic_DNA.
DR   EMBL; Z92870; CAB07436.1; JOINED; Genomic_DNA.
DR   EMBL; Z92871; CAB07436.1; JOINED; Genomic_DNA.
DR   EMBL; Z92872; CAB07436.1; JOINED; Genomic_DNA.
DR   EMBL; Z92873; CAB07436.1; JOINED; Genomic_DNA.
DR   EMBL; Z92874; CAB07436.1; JOINED; Genomic_DNA.
DR   EMBL; Z92875; CAB07436.1; JOINED; Genomic_DNA.
DR   EMBL; Z92876; CAB07436.1; JOINED; Genomic_DNA.
DR   EMBL; Z92877; CAB07436.1; JOINED; Genomic_DNA.
DR   EMBL; Z92878; CAB07436.1; JOINED; Genomic_DNA.
DR   EMBL; Z92879; CAB07436.1; JOINED; Genomic_DNA.
DR   EMBL; Z92880; CAB07436.1; JOINED; Genomic_DNA.
DR   EMBL; Z92881; CAB07436.1; JOINED; Genomic_DNA.
DR   EMBL; Z92882; CAB07436.1; JOINED; Genomic_DNA.
DR   EMBL; Z92883; CAB07436.1; JOINED; Genomic_DNA.
DR   EMBL; Z92884; CAB07436.1; JOINED; Genomic_DNA.
DR   EMBL; Z92885; CAB07436.1; JOINED; Genomic_DNA.
DR   EMBL; Z92868; CAB07437.1; -; Genomic_DNA.
DR   EMBL; Z92869; CAB07437.1; JOINED; Genomic_DNA.
DR   EMBL; Z92870; CAB07437.1; JOINED; Genomic_DNA.
DR   EMBL; Z92871; CAB07437.1; JOINED; Genomic_DNA.
DR   EMBL; Z92872; CAB07437.1; JOINED; Genomic_DNA.
DR   EMBL; Z92873; CAB07437.1; JOINED; Genomic_DNA.
DR   EMBL; Z92874; CAB07437.1; JOINED; Genomic_DNA.
DR   EMBL; Z92875; CAB07437.1; JOINED; Genomic_DNA.
DR   EMBL; Z92876; CAB07437.1; JOINED; Genomic_DNA.
DR   EMBL; Z92877; CAB07437.1; JOINED; Genomic_DNA.
DR   EMBL; Z92878; CAB07437.1; JOINED; Genomic_DNA.
DR   EMBL; Z92879; CAB07437.1; JOINED; Genomic_DNA.
DR   EMBL; Z92880; CAB07437.1; JOINED; Genomic_DNA.
DR   EMBL; Z92881; CAB07437.1; JOINED; Genomic_DNA.
DR   EMBL; Z92882; CAB07437.1; JOINED; Genomic_DNA.
DR   EMBL; Z92883; CAB07437.1; JOINED; Genomic_DNA.
DR   EMBL; Z92884; CAB07437.1; JOINED; Genomic_DNA.
DR   EMBL; Z92885; CAB07437.1; JOINED; Genomic_DNA.
DR   EMBL; AL391378; CAI39626.1; -; Genomic_DNA.
DR   EMBL; AC009986; CAI39626.1; JOINED; Genomic_DNA.
DR   EMBL; AC022537; CAI39626.1; JOINED; Genomic_DNA.
DR   EMBL; AC022025; CAI39626.1; JOINED; Genomic_DNA.
DR   EMBL; AC027118; CAI39626.1; JOINED; Genomic_DNA.
DR   EMBL; AL731537; CAI39626.1; JOINED; Genomic_DNA.
DR   EMBL; AL928686; CAI39626.1; JOINED; Genomic_DNA.
DR   EMBL; AL157399; CAI39626.1; JOINED; Genomic_DNA.
DR   EMBL; AC026228; CAI39626.1; JOINED; Genomic_DNA.
DR   EMBL; AL928686; CAI40743.1; -; Genomic_DNA.
DR   EMBL; AC009986; CAI40743.1; JOINED; Genomic_DNA.
DR   EMBL; AC022537; CAI40743.1; JOINED; Genomic_DNA.
DR   EMBL; AL731537; CAI40743.1; JOINED; Genomic_DNA.
DR   EMBL; AL391378; CAI40743.1; JOINED; Genomic_DNA.
DR   EMBL; AL157399; CAI40743.1; JOINED; Genomic_DNA.
DR   EMBL; AC027118; CAI40743.1; JOINED; Genomic_DNA.
DR   EMBL; AC026228; CAI40743.1; JOINED; Genomic_DNA.
DR   EMBL; AC022025; CAI40743.1; JOINED; Genomic_DNA.
DR   EMBL; AL157399; CAI41305.1; -; Genomic_DNA.
DR   EMBL; AC022025; CAI41305.1; JOINED; Genomic_DNA.
DR   EMBL; AC009986; CAI41305.1; JOINED; Genomic_DNA.
DR   EMBL; AL928686; CAI41305.1; JOINED; Genomic_DNA.
DR   EMBL; AL731537; CAI41305.1; JOINED; Genomic_DNA.
DR   EMBL; AL391378; CAI41305.1; JOINED; Genomic_DNA.
DR   EMBL; AC027118; CAI41305.1; JOINED; Genomic_DNA.
DR   EMBL; AC026228; CAI41305.1; JOINED; Genomic_DNA.
DR   EMBL; AC022537; CAI41305.1; JOINED; Genomic_DNA.
DR   EMBL; AL731537; CAI17115.1; -; Genomic_DNA.
DR   EMBL; AL928686; CAI17115.1; JOINED; Genomic_DNA.
DR   EMBL; AL391378; CAI17115.1; JOINED; Genomic_DNA.
DR   EMBL; AL157399; CAI17115.1; JOINED; Genomic_DNA.
DR   EMBL; AC027118; CAI17115.1; JOINED; Genomic_DNA.
DR   EMBL; AC026228; CAI17115.1; JOINED; Genomic_DNA.
DR   EMBL; AC022537; CAI17115.1; JOINED; Genomic_DNA.
DR   EMBL; AC022025; CAI17115.1; JOINED; Genomic_DNA.
DR   EMBL; AC009986; CAI17115.1; JOINED; Genomic_DNA.
DR   EMBL; AC068062; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC069079; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AC073584; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL596105; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; AL607031; -; NOT_ANNOTATED_CDS; Genomic_DNA.
DR   EMBL; CH471083; EAW54140.1; -; Genomic_DNA.
DR   EMBL; BC062688; AAH62688.1; -; mRNA.
DR   EMBL; BC127090; AAI27091.1; -; mRNA.
DR   CCDS; CCDS44399.1; -. [Q13976-1]
DR   CCDS; CCDS7244.1; -. [Q13976-2]
DR   PIR; S05702; S05702.
DR   RefSeq; NP_001091982.1; NM_001098512.2. [Q13976-1]
DR   RefSeq; NP_006249.1; NM_006258.3. [Q13976-2]
DR   UniGene; Hs.407535; -.
DR   PDB; 1ZXA; NMR; -; A/B=2-59.
DR   PDB; 3NMD; X-ray; 2.27 A; A/B/C/D/E=4-55.
DR   PDB; 3OCP; X-ray; 2.49 A; A/B=90-212.
DR   PDB; 3OD0; X-ray; 2.90 A; A/B=90-212.
DR   PDB; 3OGJ; X-ray; 2.75 A; A/B/C/D=90-212.
DR   PDB; 4KU7; X-ray; 1.65 A; A=204-354.
DR   PDB; 4KU8; X-ray; 1.99 A; A/B/C=204-354.
DR   PDB; 4QX5; X-ray; 1.32 A; A=204-354.
DR   PDB; 4QXK; Other; 2.20 A; A=204-354.
DR   PDB; 4R4L; X-ray; 2.25 A; A/B/C=2-48.
DR   PDB; 4R4M; X-ray; 1.92 A; A/B/C=2-48.
DR   PDB; 4Z07; X-ray; 2.50 A; A/C/E=86-336.
DR   PDBsum; 1ZXA; -.
DR   PDBsum; 3NMD; -.
DR   PDBsum; 3OCP; -.
DR   PDBsum; 3OD0; -.
DR   PDBsum; 3OGJ; -.
DR   PDBsum; 4KU7; -.
DR   PDBsum; 4KU8; -.
DR   PDBsum; 4QX5; -.
DR   PDBsum; 4QXK; -.
DR   PDBsum; 4R4L; -.
DR   PDBsum; 4R4M; -.
DR   PDBsum; 4Z07; -.
DR   ProteinModelPortal; Q13976; -.
DR   SMR; Q13976; -.
DR   BioGrid; 111578; 26.
DR   DIP; DIP-41118N; -.
DR   DIP; DIP-46288N; -.
DR   IntAct; Q13976; 8.
DR   MINT; MINT-121708; -.
DR   BindingDB; Q13976; -.
DR   ChEMBL; CHEMBL4273; -.
DR   GuidetoPHARMACOLOGY; 1492; -.
DR   iPTMnet; Q13976; -.
DR   PhosphoSitePlus; Q13976; -.
DR   BioMuta; PRKG1; -.
DR   DMDM; 6225588; -.
DR   EPD; Q13976; -.
DR   MaxQB; Q13976; -.
DR   PeptideAtlas; Q13976; -.
DR   PRIDE; Q13976; -.
DR   DNASU; 5592; -.
DR   Ensembl; ENST00000373980; ENSP00000363092; ENSG00000185532. [Q13976-2]
DR   Ensembl; ENST00000373985; ENSP00000363097; ENSG00000185532. [Q13976-1]
DR   GeneID; 5592; -.
DR   KEGG; hsa:5592; -.
DR   UCSC; uc001jjo.4; human. [Q13976-1]
DR   CTD; 5592; -.
DR   DisGeNET; 5592; -.
DR   GeneCards; PRKG1; -.
DR   HGNC; HGNC:9414; PRKG1.
DR   HPA; CAB009629; -.
DR   HPA; HPA007699; -.
DR   MalaCards; PRKG1; -.
DR   MIM; 176894; gene.
DR   MIM; 615436; phenotype.
DR   neXtProt; NX_Q13976; -.
DR   OpenTargets; ENSG00000185532; -.
DR   Orphanet; 91387; Familial thoracic aortic aneurysm and aortic dissection.
DR   PharmGKB; PA33777; -.
DR   GeneTree; ENSGT00810000125385; -.
DR   HOGENOM; HOG000233033; -.
DR   HOVERGEN; HBG006211; -.
DR   InParanoid; Q13976; -.
DR   KO; K07376; -.
DR   OMA; YAKSDWS; -.
DR   OrthoDB; EOG091G0S9R; -.
DR   PhylomeDB; Q13976; -.
DR   TreeFam; TF313261; -.
DR   BRENDA; 2.7.11.12; 2681.
DR   Reactome; R-HSA-392517; Rap1 signalling.
DR   Reactome; R-HSA-4086398; Ca2+ pathway.
DR   Reactome; R-HSA-418457; cGMP effects.
DR   SABIO-RK; Q13976; -.
DR   SignaLink; Q13976; -.
DR   SIGNOR; Q13976; -.
DR   ChiTaRS; PRKG1; human.
DR   EvolutionaryTrace; Q13976; -.
DR   GeneWiki; PRKG1; -.
DR   GenomeRNAi; 5592; -.
DR   PRO; PR:Q13976; -.
DR   Proteomes; UP000005640; Chromosome 10.
DR   Bgee; ENSG00000185532; -.
DR   CleanEx; HS_PRKG1; -.
DR   ExpressionAtlas; Q13976; baseline and differential.
DR   Genevisible; Q13976; HS.
DR   GO; GO:0005737; C:cytoplasm; IDA:UniProtKB.
DR   GO; GO:0005829; C:cytosol; TAS:Reactome.
DR   GO; GO:0005794; C:Golgi apparatus; IEA:Ensembl.
DR   GO; GO:0005886; C:plasma membrane; IDA:UniProtKB.
DR   GO; GO:0005524; F:ATP binding; IEA:UniProtKB-KW.
DR   GO; GO:0005246; F:calcium channel regulator activity; IDA:UniProtKB.
DR   GO; GO:0030553; F:cGMP binding; IEA:UniProtKB-KW.
DR   GO; GO:0004692; F:cGMP-dependent protein kinase activity; IDA:UniProtKB.
DR   GO; GO:0004674; F:protein serine/threonine kinase activity; TAS:Reactome.
DR   GO; GO:0030036; P:actin cytoskeleton organization; TAS:ProtInc.
DR   GO; GO:0019934; P:cGMP-mediated signaling; IEA:Ensembl.
DR   GO; GO:0016358; P:dendrite development; IEA:Ensembl.
DR   GO; GO:0030900; P:forebrain development; IEA:Ensembl.
DR   GO; GO:0090331; P:negative regulation of platelet aggregation; IMP:UniProtKB.
DR   GO; GO:0001764; P:neuron migration; IEA:Ensembl.
DR   GO; GO:0006468; P:protein phosphorylation; TAS:ProtInc.
DR   GO; GO:0043087; P:regulation of GTPase activity; IMP:UniProtKB.
DR   GO; GO:0060087; P:relaxation of vascular smooth muscle; IEA:Ensembl.
DR   GO; GO:0007165; P:signal transduction; TAS:ProtInc.
DR   Gene3D; 2.60.120.10; -; 2.
DR   InterPro; IPR000961; AGC-kinase_C.
DR   InterPro; IPR002374; cGMP_dep_kinase.
DR   InterPro; IPR018490; cNMP-bd-like.
DR   InterPro; IPR018488; cNMP-bd_CS.
DR   InterPro; IPR000595; cNMP-bd_dom.
DR   InterPro; IPR011009; Kinase-like_dom.
DR   InterPro; IPR031831; PKcGMP_CC.
DR   InterPro; IPR000719; Prot_kinase_dom.
DR   InterPro; IPR017441; Protein_kinase_ATP_BS.
DR   InterPro; IPR014710; RmlC-like_jellyroll.
DR   InterPro; IPR008271; Ser/Thr_kinase_AS.
DR   Pfam; PF00027; cNMP_binding; 2.
DR   Pfam; PF16808; PKcGMP_CC; 1.
DR   Pfam; PF00069; Pkinase; 1.
DR   PIRSF; PIRSF000559; cGMP-dep_kinase; 1.
DR   PRINTS; PR00104; CGMPKINASE.
DR   SMART; SM00100; cNMP; 2.
DR   SMART; SM00133; S_TK_X; 1.
DR   SMART; SM00220; S_TKc; 1.
DR   SUPFAM; SSF51206; SSF51206; 2.
DR   SUPFAM; SSF56112; SSF56112; 1.
DR   PROSITE; PS51285; AGC_KINASE_CTER; 1.
DR   PROSITE; PS00888; CNMP_BINDING_1; 2.
DR   PROSITE; PS00889; CNMP_BINDING_2; 2.
DR   PROSITE; PS50042; CNMP_BINDING_3; 2.
DR   PROSITE; PS00107; PROTEIN_KINASE_ATP; 1.
DR   PROSITE; PS50011; PROTEIN_KINASE_DOM; 1.
DR   PROSITE; PS00108; PROTEIN_KINASE_ST; 1.
PE   1: Evidence at protein level;
KW   3D-structure; Acetylation; Allosteric enzyme; Alternative splicing;
KW   Aortic aneurysm; ATP-binding; cGMP; cGMP-binding; Coiled coil;
KW   Complete proteome; Cytoplasm; Disease mutation; Disulfide bond;
KW   Kinase; Nucleotide-binding; Phosphoprotein; Polymorphism;
KW   Reference proteome; Serine/threonine-protein kinase; Transferase.
FT   INIT_MET      1      1       Removed. {ECO:0000244|PubMed:22223895}.
FT   CHAIN         2    671       cGMP-dependent protein kinase 1.
FT                                /FTId=PRO_0000086115.
FT   DOMAIN      360    619       Protein kinase. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   DOMAIN      620    671       AGC-kinase C-terminal.
FT   NP_BIND     167    170       cAMP or cGMP 1. {ECO:0000244|PDB:3OCP,
FT                                ECO:0000244|PDB:3OD0,
FT                                ECO:0000244|PDB:3OGJ,
FT                                ECO:0000269|PubMed:21526164}.
FT   NP_BIND     177    178       cAMP or cGMP 1. {ECO:0000244|PDB:3OCP,
FT                                ECO:0000244|PDB:3OD0,
FT                                ECO:0000244|PDB:3OGJ,
FT                                ECO:0000269|PubMed:21526164}.
FT   NP_BIND     291    294       cAMP or cGMP 2. {ECO:0000244|PDB:4KU7,
FT                                ECO:0000244|PDB:4QX5,
FT                                ECO:0000244|PDB:4QXK,
FT                                ECO:0000269|PubMed:24239458,
FT                                ECO:0000269|PubMed:25271401}.
FT   NP_BIND     301    302       cAMP or cGMP 2. {ECO:0000244|PDB:4KU7,
FT                                ECO:0000244|PDB:4QX5,
FT                                ECO:0000244|PDB:4QXK,
FT                                ECO:0000269|PubMed:24239458,
FT                                ECO:0000269|PubMed:25271401}.
FT   NP_BIND     366    374       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   REGION        2    102       Required for dimerization.
FT   REGION        9     44       Leucine-zipper.
FT   REGION       50     75       Autoinhibitory domain. {ECO:0000250}.
FT   REGION      103    220       cGMP-binding, high affinity.
FT   REGION      221    341       cGMP-binding, low affinity.
FT   COILED        2     59       {ECO:0000269|PubMed:16131665}.
FT   ACT_SITE    484    484       Proton acceptor. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159, ECO:0000255|PROSITE-
FT                                ProRule:PRU10027}.
FT   BINDING     282    282       cGMP 2. {ECO:0000244|PDB:4KU7,
FT                                ECO:0000244|PDB:4QX5,
FT                                ECO:0000244|PDB:4QXK,
FT                                ECO:0000269|PubMed:24239458,
FT                                ECO:0000269|PubMed:25271401}.
FT   BINDING     336    336       cAMP or cGMP 2. {ECO:0000244|PDB:4KU7,
FT                                ECO:0000244|PDB:4QX5,
FT                                ECO:0000244|PDB:4QXK,
FT                                ECO:0000269|PubMed:24239458,
FT                                ECO:0000269|PubMed:25271401}.
FT   BINDING     390    390       ATP. {ECO:0000255|PROSITE-
FT                                ProRule:PRU00159}.
FT   MOD_RES       2      2       N-acetylserine.
FT                                {ECO:0000244|PubMed:22223895}.
FT   MOD_RES      59     59       Phosphothreonine; by autocatalysis.
FT                                {ECO:0000250}.
FT   MOD_RES     515    515       Phosphothreonine.
FT                                {ECO:0000250|UniProtKB:P0C605}.
FT   DISULFID     43     43       Interchain. {ECO:0000250}.
FT   VAR_SEQ       1     89       MSELEEDFAKILMLKEERIKELEKRLSEKEEEIQELKRKLH
FT                                KCQSVLPVPSTHIGPRTTRAQGISAEPQTYRSFHDLRQAFR
FT                                KFTKSER -> MGTLRDLQYALQEKIEELRQRDALIDELEL
FT                                ELDQKDELIQKLQNELDKYRSVIRPATQQAQKQSASTLQGE
FT                                PRTKRQAISAEPTAFDIQDLSHVTLPFYPKSPQ (in
FT                                isoform Beta).
FT                                {ECO:0000303|PubMed:15489334,
FT                                ECO:0000303|PubMed:17974005,
FT                                ECO:0000303|PubMed:2792381}.
FT                                /FTId=VSP_038714.
FT   VAR_SEQ       1     15       MSELEEDFAKILMLK -> MEKQNMFLHGSYILR (in
FT                                isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055541.
FT   VAR_SEQ      16    297       Missing (in isoform 3).
FT                                {ECO:0000303|PubMed:14702039}.
FT                                /FTId=VSP_055542.
FT   VARIANT     177    177       R -> Q (in AAT8; impairs cGMP binding;
FT                                the mutant protein is constitutively
FT                                active; dbSNP:rs397515330).
FT                                {ECO:0000269|PubMed:23910461}.
FT                                /FTId=VAR_070434.
FT   VARIANT     249    249       I -> V (in dbSNP:rs56082459).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_046773.
FT   VARIANT     267    267       N -> S (in dbSNP:rs34997494).
FT                                {ECO:0000269|PubMed:17344846}.
FT                                /FTId=VAR_051632.
FT   VARIANT     474    474       Y -> F (in dbSNP:rs149710600).
FT                                {ECO:0000269|PubMed:23910461}.
FT                                /FTId=VAR_070435.
FT   VARIANT     666    666       G -> A (in dbSNP:rs750949508).
FT                                {ECO:0000269|PubMed:23910461}.
FT                                /FTId=VAR_070436.
FT   MUTAGEN      12     12       L->A: Loss of binding to PPP1R12A.
FT                                {ECO:0000269|PubMed:10567269}.
FT   MUTAGEN      19     19       I->A: Loss of binding to PPP1R12A.
FT                                {ECO:0000269|PubMed:10567269}.
FT   MUTAGEN      26     26       L->P: Loss of binding to PPP1R12A.
FT                                {ECO:0000269|PubMed:10567269}.
FT   MUTAGEN      33     33       I->A: Loss of binding to PPP1R12A.
FT                                {ECO:0000269|PubMed:10567269}.
FT   MUTAGEN      40     40       L->A: Loss of binding to PPP1R12A.
FT                                {ECO:0000269|PubMed:10567269}.
FT   MUTAGEN     281    281       L->A: Reduces cGMP binding affinity.
FT                                {ECO:0000269|PubMed:24239458}.
FT   MUTAGEN     282    282       R->A: Reduces cGMP binding affinity.
FT                                {ECO:0000269|PubMed:24239458}.
FT   MUTAGEN     302    302       T->A: Reduces cGMP binding affinity.
FT                                {ECO:0000269|PubMed:24239458}.
FT   MUTAGEN     336    336       Y->A: Reduces cGMP binding affinity.
FT                                {ECO:0000269|PubMed:24239458}.
FT   HELIX         3     44       {ECO:0000244|PDB:4R4M}.
FT   HELIX        90    100       {ECO:0000244|PDB:3OCP}.
FT   TURN        102    106       {ECO:0000244|PDB:3OCP}.
FT   HELIX       109    118       {ECO:0000244|PDB:3OCP}.
FT   STRAND      120    124       {ECO:0000244|PDB:3OCP}.
FT   STRAND      129    131       {ECO:0000244|PDB:3OCP}.
FT   STRAND      139    145       {ECO:0000244|PDB:3OCP}.
FT   STRAND      148    152       {ECO:0000244|PDB:3OCP}.
FT   STRAND      155    160       {ECO:0000244|PDB:3OCP}.
FT   STRAND      165    167       {ECO:0000244|PDB:3OCP}.
FT   HELIX       169    173       {ECO:0000244|PDB:3OCP}.
FT   STRAND      174    176       {ECO:0000244|PDB:3OD0}.
FT   STRAND      178    185       {ECO:0000244|PDB:3OCP}.
FT   STRAND      187    193       {ECO:0000244|PDB:3OCP}.
FT   HELIX       194    201       {ECO:0000244|PDB:3OCP}.
FT   HELIX       208    218       {ECO:0000244|PDB:4QX5}.
FT   TURN        220    224       {ECO:0000244|PDB:4QX5}.
FT   HELIX       227    236       {ECO:0000244|PDB:4QX5}.
FT   STRAND      238    242       {ECO:0000244|PDB:4QX5}.
FT   STRAND      247    249       {ECO:0000244|PDB:4QX5}.
FT   STRAND      257    264       {ECO:0000244|PDB:4QX5}.
FT   STRAND      266    270       {ECO:0000244|PDB:4QX5}.
FT   STRAND      274    276       {ECO:0000244|PDB:4KU8}.
FT   STRAND      279    284       {ECO:0000244|PDB:4QX5}.
FT   HELIX       293    295       {ECO:0000244|PDB:4QX5}.
FT   STRAND      296    298       {ECO:0000244|PDB:4QX5}.
FT   STRAND      303    317       {ECO:0000244|PDB:4QX5}.
FT   HELIX       318    324       {ECO:0000244|PDB:4QX5}.
FT   TURN        325    327       {ECO:0000244|PDB:4QX5}.
FT   HELIX       329    332       {ECO:0000244|PDB:4QX5}.
SQ   SEQUENCE   671 AA;  76364 MW;  51389502A5E5FBD2 CRC64;
     MSELEEDFAK ILMLKEERIK ELEKRLSEKE EEIQELKRKL HKCQSVLPVP STHIGPRTTR
     AQGISAEPQT YRSFHDLRQA FRKFTKSERS KDLIKEAILD NDFMKNLELS QIQEIVDCMY
     PVEYGKDSCI IKEGDVGSLV YVMEDGKVEV TKEGVKLCTM GPGKVFGELA ILYNCTRTAT
     VKTLVNVKLW AIDRQCFQTI MMRTGLIKHT EYMEFLKSVP TFQSLPEEIL SKLADVLEET
     HYENGEYIIR QGARGDTFFI ISKGTVNVTR EDSPSEDPVF LRTLGKGDWF GEKALQGEDV
     RTANVIAAEA VTCLVIDRDS FKHLIGGLDD VSNKAYEDAE AKAKYEAEAA FFANLKLSDF
     NIIDTLGVGG FGRVELVQLK SEESKTFAMK ILKKRHIVDT RQQEHIRSEK QIMQGAHSDF
     IVRLYRTFKD SKYLYMLMEA CLGGELWTIL RDRGSFEDST TRFYTACVVE AFAYLHSKGI
     IYRDLKPENL ILDHRGYAKL VDFGFAKKIG FGKKTWTFCG TPEYVAPEII LNKGHDISAD
     YWSLGILMYE LLTGSPPFSG PDPMKTYNII LRGIDMIEFP KKIAKNAANL IKKLCRDNPS
     ERLGNLKNGV KDIQKHKWFE GFNWEGLRKG TLTPPIIPSV ASPTDTSNFD SFPEDNDEPP
     PDDNSGWDID F
//
